Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain
Mei Yang, Jiaqi Li, Zhaoxia Huang, Heng Li, Yueming Wang, Xiaoli Wang, Sisi Kang, Xing Huang, Changwen Wu, Tong Liu, Zhenxing Jia, Junlang Liang, Xiaohui Yuan, Suhua He, Xiaoxue Chen, Zhechong Zhou, Qiuyue Chen, Siqi Liu, Jing Li, Huiwen Zheng, Xi Liu, Kenan Li, Xiaojun Yao, Bin Lang, Longding Liu, Hua‐Xin Liao, Shoudeng Chen
Abstract
COVID-19 is a respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The COVID-19 pandemic has posed a serious threat to global health and the economy, so it is necessary to find safe and effective antibody drugs and treatments. The receptor-binding domain (RBD) in the SARS-CoV-2 spike protein is responsible for binding to the angiotensin-converting enzyme 2 (ACE2) receptor. It contains a variety of dominant neutralizing epitopes and is an important antigen for the development of new coronavirus antibodies. The significance of our research lies in the determination of new epitopes, the discovery of antibodies against RBD, and the evaluation of the antibodies' neutralizing effect. The identified antibodies here may be drug candidates for the development of clinical interventions for SARS-CoV-2.